Pharmacotherapy is widely recognized as the single most effective treatment for schizophrenia (Davis and Cole 1975; May 1968) . For most patients, it offers the advantages of higher reliability, greater effectiveness, easier accessibility, and fewer hazards than any other known treatment (Lehmann 1975) . Furthermore, the introduction of neuroleptics in the mid-1950s is believed to have played a major role in the ensuing dramatic declines in the number of hospitalized schizophrenics (Zirkle 1973) . In 1964, Bannister, Salmon, and Leiberman reported that the highest diagnosis-treatment relationship in psychiatry existed between schizophrenia and treatment with phenothiazines. (Today, this claim might be made for manicdepressive illness and lithium.) According to Lehmann (1975) , the most significant achievement of long-term neuroleptic therapy has been its impact on the high relapse rate in chronic schizophrenic patients in remission. Indeed, much of the medical profession considers that the community mental health movement would not have been possible without the treatment of the mentally ill with neuroleptics (Crane 1973n) . By the end of 1970, an estitimated 250 million people had been treated with neuroleptics (Ayd 1970)-ample evidence of the widespread acceptance of pharmacotherapy.
Nonetheless, during the last decade, considerable concern has been expressed about the adverse effects of long-term treatment with neuroleptics. The principal complication is tardive dyskinesia (T.D.), an involuntary movement disorder whose incidence is sometimes reported to be as high as 60 percent among chronic psychiatric patients. The persistence of this syndrome even after neuroleptics have been withdrawn, its resistance to most available treatments, and reports of irreversible brain damage in post mortem examinations of patients with T.D. are rather disquieting. Crane (1973<?) contends that the syndrome will probably prove to be 252 SCHIZOPHRENIA BULLETIN a major limiting factor in long-term prescription of neuroleptics. It is not surprising, therefore, that the ethical and legal dilemmas raised by T.D. are receiving increased attention (Ayd 1977) . Patients have sued their psychiatrists for not having taken adequate steps to prevent or reverse dyskinesia, and there is now considerable debate among psychiatrists about the need to obtain informed consent before prescribing neuroleptics. Reflecting this growing concern, the American Psychiatric Association has appointed a task force to study the problem.
It is thus imperative for all those concerned with the use of neuroleptics-mainly, but not exclusively, in the treatment of schizophrenia-to be familiar with T.D. Despite an ever-increasing literature on the. subject, there are few exhaustive reviews of treatment of this disorder. In the present article we have attempted to include as many studies on the treatment of T.D. published in the English language until August 1978 as possible.
Tardlve Dysklnesia
Schonecker first described three cases of tardive dyskinesia in 1957. In the following 10 years, 600 new cases were reported in 37 articles. During the subsequent 5 years , 60 articles on T.D. were published, and 1,200 new patients were described (Crane 1973b) . Clearly, the literature is growing at a rapid rate.
Symptoms. These essentially consist of slow, rhythmical, automatic, stereotyped movements, particularly in the buccolingual masticatory area (e.g., smacking of lips, protrusion of tongue, and puffing of cheeks), extremities, and trunk muscles. Usually adults «;Vinw oral tjyfkinpsia. while children (in whom the disorder is very uncommon) exhibit "chor'eirorrnjnovements of limbs. These abnormal movements are reduced by voluntary activity of muscles in the affected areas and, temporarily, by volition. They are increased by movements in distant parts of the body and by stress. The dyskinesia disappears during sleep. A brief description of the syndrome has been published by the American College of Neuropsychopharmacology/Food and Drug Administration task force (Schiele et al. 1973) .
Etiology. T.D. is most common in
elderly patients who have been treated with neuroleptics for a number of years. The reported prevalence of the syndrome among patients on neuroleptics is highly variable, ranging from .5 percent to over 60 percent. It is believed that long-term use of neuroleptics (gioat of which block dopamine receptors j in the nierostriatum and in the brain) produces a state of denervation supersensitivity of nigrostriatal dopamine receptors. The result ing hvjigxgens^^/i^^todoDam^^e. is presumed to.hp responsible for T n RprpnMy cholinergic hypofunction in the extrapyramidal system has also been suspected to play a role in the production of T.D. However, little is definitely known about etiological mechanisms or predisposing constitutional factors. Figures 1 and 2 illustrate two current theories on the pathophysiology of T.D.
Course. T.D. may first appear when a patient's dose of neuroleptics is lowered or discontinued, but it often develops without any change in medication. Although T.D. initially becomes worse when neuroleptics are discontinued, it tends to disappear within a few weeks or months after neuroleptic withdrawal in a variable proportion of patients. Elderly and brain-damaged patients are more likely to have persistent dyskinesia.
Differential Diagnosis. Local conditions causing oral dyskinesia (e.g., illfitting dentures), neurological diseases (such as Huntington's chorea), it disorder sySKinesias due to otner drugs (such as L-dopa) should be distinguished from T.D.
A short description of the various aspects of tardive dyskinesia will be published elsewhere (Jeste et al., in press ).
Treatment for Tardlve Dysklnesia
Until the end of 1969, the only reported treatments for T.D. were the administration or withdrawal of neuroleptics, the use of antiparkinsonian agents, and such nondrug treatments as dental prosthesis^e-conditioning, and stereotactic surgery. Although, until recently, most of the studies conducted were nonblind, a number of controlled, double-blind studies using a wide range of drugs have been carried out during the last few years. It is interesting to note that most of these investigations were based on some theoretical rationale about the mechanism of action of the treatments being tested. Although the neuropathology underlying T.D., as well as the mode of action of the treatments used to combat it, so far has eluded clear understanding, the therapeutic maneuvers have had a significant impact on our current knowledge of the syndrome. Moreover, these studies have challenged the therapeutic nihilism that has surrounded the concept of irreversible T.D.
The principal treatments for T.D. may be categorized under the following headings:
Neuroleptics
The first article on treatment of T.D. with a neuroleptic-tetrabenazine-appeared in 1961. Brandrup's (1961) trial of this drug was prompted by reports of its use for the relief of symptoms of Huntington's chorea. Later, as the etiological association between neuroleptics and T.D. became more apparent, there was an understandable reluctance to treat the disorder with the same drugs by which it presumably had been caused. However, an increasing number of reports of persistent T.D., which did not respond to other drugs, and a need to continue using neuroleptics in some Based on a finding that T.D. was uncommon in patients on monoamine oxidase inhibitors, Bucci (1971) used chlorpromazine and isocarboxazid in the treatment of T.D. and obtained positive results. Theoretically, however, monoamine oxidase inhibitors would be expected to increase DA, and thus worsen T.D. Jeste, Olgiati, and Ghali (1977) compared the effects of single daily administration and multiple daily administration of chlorpromazine. The total daily dose was kept constant during both phases. T.D. was found to improve significantly during the multiple daily administration schedule. The authors postulated a "masking" effect of the latter schedule, probably due to a relatively steady blood-neuroleptic concentration and DA receptor blockade.
Other DA Antagonists
Oxypertine is a DA-depleting agent (Chien, Jung, and Ross-Townsend 1978) .
The metabolic product of methyl dopa is methyl dopamine, which acts as a false neurotransmitter and competes with DA for the receptors (Kazamatsuri, Chien, and Cole 1972n) . It probably also has an effect on presynaptic DA stores.
AMPT (alpha-methyl-para-tyrosine) reduces formation of DA by inhibiting the rate-limiting enzyme, tyrosine hydroxylase (Gerlach, Reisby, and Randrup 1974) .
Papaverine, a smooth muscle relaxant, antagonizes DA in the caudate nucleus of the rat .
Apomorphine in large doses has a DA agonist action on postsynaptic receptors. In small doses, however, it is presumed to act on presynaptic DA receptors that are inhibitory in nature (Carroll, Curtis, and Kokmen 1977) .
Droperidol is a DA antagonist (Casey and Denney 1977) .
See table 2 for a list of studies with DA antagonists.
Cholinerglc Drugs
The first reports of successful use of physostigmine (Fann et al.) and deanol (Casey and Denney; Miller) were published in 1974 (see table 3 ). It was reasoned that these agents increased functional acetylcholine (ACh) in the brain, mainly in the nigrostriatal system and thus restored the DA-ACh balance there to a normal state. The rationale is based on clinical and animal studies suggesting a DA-ACh balance in the nigrostriatum. It has been known that parkinsonism improves (symptomatically) with either dopaminergic (e.g., L-dopa) or anticholinergic (e.g., trihexyphenidyl) drugs, while it is made worse by antidopaminergic (e.g., phenothiazines) or cholinomimetic (e.g., physostigmine) agents. It is postulated that parkinsonism results from nigrostriatal DA deficiency, which in turn produces a relative ACh hyperactivity. The reverse holds true for Huntington's chorea, which is somewhat improved by treatment with phenothiazines and physostigmine.
Since T.D. is presumed to have some biochemical similarities to Huntington's chorea, the use of cholinergic drugs in its treatment is a logical step. Furthermore, physostigmine and deanol have also been shown to have salutary effects in at least some patients with L-dopainduced dyskinesia, which is similar to T.D. both phenomenologically and (probably) neurochemically.
Physostigmine is a reversible anticholinesterase and produces a shortterm increase in brain ACh content. The mode of action of deanol is, however, controversial. According to some, but not all, investigators, it acts as a precursor of ACh and thus increases brain ACh content.
The other cholinergic drugs used in the treatment of T.D.-choline (Growdon et al. 1977 ) and lecithin (Growdon et al. 1978 )-have been shown to be precursors of ACh. Stevens, Wilson, and Foote (1974) demonstrated that GABA (gammaaminobutyric acid) is an inhibitory neurotransmitter and is linked with nigrostriatal DA functions. On this basis, Linnoila, Viukari, and Hietala (1976) hypothesized that GABA'-ergic agents such as sodium valproate might be useful for treating T.D. through their inhibition of the DA neuronal supersensitivity in the nigrostriatum.
GABA'erglc Drugs
Benzodiazepines, such as diazepam and clonazepam, are thought to have central GABA'ergic action. In view of the theory about the DA-ACh balance in the extrapyramidal system, discussed above, one would expect a worsening of T.D. with a drug like amantadine. Indeed, all the studies which preceded and followed the two mentioned above reported negative results (Crane 1971n; Dynes 1970; Janowsky et al. 1972; Merren 1972) . L-dopa, as a dopamine agonist, would be expected to aggravate T.D. However, Friedhoff and Alpert (1978) have suggested that longterm treatment with L-dopa probably reduces DA receptor sensitivity and, thus, helps in the treatment of T.D.
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Methylphenidate produces amphetamine-like central stimulation, with increased catecholamine activity. (See table 5.)
Antlchollnergic Orugs
Anticfiolinergic drugs used in the treatment of idiopathic and druginduced parkinsonism were tried for T.D., since both parkinsonism and T.D. ar*extrapyramidal system disorders. However, most investigators (Bullock 1972; Carroll, Curtis, and Kokmen 1977; Druckman, Seelinger, and Thulin 1962; Hunter, Earl, and Thornicroff 1964; Evans 1965; Schmidt and Jarcho 1966; Sovner and DiMascio 1978) found that these drugs did not reduce T.D. and often aggravated the condition. It has even been proposed that antiparkinsonian agents may predispose to T.D. (Klawans 1976 ). There are a number of individual case reports in which anticholinergic drugs were found to be ineffective in the treatment of T.D. We have not listed these case reports in table 6. That table includes only those investigations in which anticholinergic drugs were tried in a significant number of patients with T.D.
The most commonly prescribed anticholinergic drugs for extrapyramidal disorders have been trihexyphenidyl (Dynes 1970; Turek et al. 1972) , biperiden (Gerlach, Reisby, and Randrup 1974) , and benztropine (Casey and Denney 1977; Jus et al. 1974) . Benztropine is a synthetic compound consisting of active ingredients of atropine and diphenhydramine (an antihistamine).
Miscellaneous Drugs
Pyridoxine (Vitamin B 6 ) was found to diminish the effects of L-dopa in parkinsonian patients. This provided the rationale for its use in T.D. (Crane, Turek, and Kurland 1970) .
In 1973, lithium was reported to be an effective treatment for T.D. by Prange et al. and Dalen. These investigators suggested that the action of lithium in diminishing central catecholaminergic activity or in stabilizing the sensitivity of a minecontaining systems in the central nervous system might be helpful. In a later study, Cerlach, Thorsen, and Munkvad (1975) considered a third possibility-that the antihyperkinetic effect of lithium might be merely secondary to its inhibitory effect on psychomotor activity. Recent studies on animal models of T.D. show that lithium does not reduce an already established neuroleptic-induced supersensitivity and thus may not reduce T.D. (Pert et al. 1978) .
(Lithium, however, may be helpful, according to these investigators, in preventing the supersensitivity if given concomitantly with the neuroleptics.) Indeed, several patients in whom T.D. was aggravated with lithium have been described (Rosenbaum et al. 1977) .
Tryptophan was used on the basis of reports that it (along with pyridoxine) aggravated parkinsonism and so might reduce T.D. (Prange et al. 1973) .
M.I.F.-I (Melanocyte-stimulating hormone release Inhibiting Factor I) was observed to reduce L-dopainduced dyskinesia in parkinsonian patients. Ehrensing (1974) and Ehrensing et al. (1977) , postulating that M.I.F.-I might act as a stabilizer of DA receptors, used it in patients with T.D.
Diphenylhydantoin, the wellknown anticonvulsant, was tried in the treatment of T.D. following reports that it was effective in chorea minor (? Sydenham's chorea) and controversial in parkinsonism (Jus et al. 1974) .
Manganese chelate received attention when Kunin (1976) claimed that T.D. was associated with a deficiency of manganese and would respond to manganese administration.
Cyproheptadine is a strong serotonin antagonist (Goldman 1976) .
Baclofen was used by Korsgaard (1976) as a GABA'ergic agent in the treatment of T.D. Recent studies, however, suggest that baclofen is an antagonist of substance P and not a GABA agonist (Simpson et al. 1978) .
Barbiturates act as sedatives and may help in a few patients with T.D. (Lipsius 1977) . They are, however, ineffective in the majority of T.D. cases (Sovner and Loadman 1978) .
Fusaric acid inhibits dopaminebeta-hydroxylase and thus reduces norepinephrine synthesis. It increases serotonin concentrations but has no effect on DA concentration in the brain (Viukari and Linnoila 1977) . (See table 7.)
Neuroleptlc Withdrawal
It is logical that the first step in the treatment of a presumed iatrogenic disorder should be withdrawal of the offending drugs. In one of the earliest clinical studies on a significant number of T.D. patients, Uhrbrand and Faurbye (1960) found that symptoms of T.D. disappeared in younger and nonbrain-damaged patients when neuroleptics were withdrawn. A number of subsequent reports have borne this finding out. Table 8 includes only those studies in which significant numbers of patients were withdrawn from neuroleptics. Isolated case reports have not been cited. It is possible that T.D. consists of at least two subtypes-reversible and persistent-and that these two forms can be distinguished by their response to the withdrawal of neuroleptics for 3 months (Jeste et al., in press ).
Nondrug Treatment*
Studies of nondrug treatment are listed in table 9.
Prosthodontia. Using well-fitting dentures helps those patients whose oral dyskinesia is partly or entirely due to ill-fitting dentures or other prosthodontic problems (Lauciello and Appelbaum 1977).
Deconditioning. As oral dyskinesia may result from stereotyped mouth movements in response to drug' induced dryness of mouth, deconditioning would be expected to reduce these movements in some patients (Kline 1968n) . ECT. Its mode of action in T.D. not known (Price and Levin 1978) .
Methodological Issues
Diagnosis of T.D. As with most other diagnoses in psychiatry, the diagnosis of T.D. is essentially a subjective one. There are a number of conditions, such as ill-fitting dentures, Huntington's chorea, and psychotic mannerisms, which resemble T.D. in the type of abnormal movements seen. Two ways of increasing the reliability of diagnosis of T.D. are specifying the diagnostic criteria used (Jeste et al., in press) and having two or more investigators to agree on the diagnosis of T.D. in each patient in the study. Unfortunately, these procedures have not been commonly used. Several studies have been criticized on diagnostic grounds. For example, Crane (1971a) and Kazamatsuri (1971) questioned the diagnosis of T.D. in Vale and Espejel's (1971) report of successful treatment with amantadine; they contended that Vale and Espejel's patients probably had pseudoparkinsonism rather than T.D.
Characteristics of Patients.
Most reported studies give patients' age, sex, and psychiatric diagnosis, although there are a few exceptions. In view of the suggestion that T.D. tends to be reversible in younger and nonbrain-damaged subjects, such information is necessary for comparing different treatment trials. It would probably be useful to describe in some detail the evidence for or against brain damage in a given patient population.
Characteristics of T.D.
Several investigators have found that oral dyskinesia responds to treatment better than limb or trunk dyskinesia (Bucci 1971; Gardos and Cole 1975; Jeste, Olgiati, and Ghali 1977) . Similarly, it has been suggested-but not conclusively demonstrated-that the longer the duration of T.D., the more likely it is to be persistent. Estimates of the duration of T.D. tend to be imprecise because of the typically insidious onset of symptoms. Study Design. Many earlier studies on the treatment of T.D. were nonblind. Because T.D. was believed to be an irreversible condition, the fact that a treatment reduced or relieved dyskinesia-was accepted as sufficient evidence of its value (Kunin 1976; Miller 1974; Vale and Espejel 1971) . It is now apparent, however, that a significant proportion of patients with T.D. are placebo responders. Thus, at least two well-conducted double-blind crossover studies (Penovich et al. 1978; Simpson et al. 1977) failed to find a significant difference between deanol and placebo. In the first study, all 10 patients (seven on deanol and three on placebo) improved during the first of the two treatment phases, but none showed further improvement during the second phase. Penovich et al. (1978) noted that of the six patients who improved with deanol, all but one also responded to placebo. Therefore, the need for double-blind placebo-controlled, crossover studies is as strong for T.D. as it is for most psychiatric disorders. The ability of a large number of apparently unrelated treatments to produce improvement in over one third of patients (table 10) also suggests that there may be a significant number of placebo responders among cases of T.D.
Assessment of Severity of Symptoms. Gardos, Cole, and LaBrie (1977) have reviewed the various methods used to assess T.D. Many investigators, particularly in recent studies, have specified their methods for assessing severity of T.D. symptoms. These usually include a variety of clinical rating scales. In a study conducted by Jus et al. (1974) , an effort was made to enhance objectivity by combining a clinical assessment procedure with a polygraphic one. Owing to the influence of various subjective and environmental factors on the severity of T.D., it is methodologically preferable to keep the time and place of ratings constant throughout the experimental period and to make unobtrusive observations. The reliability of ratings is also improved by having at least two "blind" raters and using videotapes or films to record patients' symptoms. In an interesting approach, Klawans and Rubovitz (1974) recorded the movement of a torch held by the patient to judge the severity of dyskinesia involving upper limbs. Because dyskinetic symptoms can be confused with those of other extrapyramidal disorders, such as drug-induced pseudoparkinsonism, a rating scale for the latter has been included in some drug trials. Some investigators have also studied changes in the severity of psychopathology during the treatment period in order to evaluate the possible relationship of such changes to the severity of T.D.
Length of Study.
It is interesting that in many "positive" studies patients improved within a few days of starting treatment. This finding again raises the possibility of a placebo effect. Several longer term studies (Ehrensing et al. 1977; Kazamatsuri, Chien, and Cole 1973) demonstrated that improvement usually reached its peak by the second week of treatment. At that point, the severity of T.D. again increased and then remained stable unless the dose of the drug was increased. Possible explanations for the transitory improvement are that the initial beneficial effect was a psychogenic one or that tolerance developed to the new treatment. Simpson et al. (1976 Simpson et al. ( , 1978 and Gardos and Cole (1978) Drug Dosage. Most studies on relatively large samples of patients have used fixed dosage schedules. Although this procedure is more practicable, it does not take into account differences in individual patients' needs for a drug, based on differences, for example, in their weight and severity of symptoms.
Concurrent Medications, Especially
Neuroleptics. This issue is an important one to be considered in any treatment study for T.D. It is generally agreed that in a significant proportion of patients, T.D. symptoms are masked or reduced by neuroleptics, while in many other patients, withdrawal of neuroleptics relieves T.D. Furthermore, there is a possibility of an interaction between the experimental drug and a neuroleptic, so that in a patient who is receiving both drugs simultaneously, the resultant effect on T.D. may be due to such an interaction. Thus, the evaluation of a drug's presumably specific anti-T.D. effects poses many problems. One way to avoid some of these complications would be to stop the neuroleptics at least 3 months before the study. This procedure would eliminate cases of T.D. that respond to the withdrawal of neuroleptics and would also avoid the question of the neuroleptics' interactional effects. In those patients in whom withdrawal is not feasible because of the risk of psychotic relapse, the neuroleptics should be continued at a stable dose for at Simpson et al. (1976) have referred to this distinction between statistical and clinical improvement, and the point is well illustrated in a study by Gardos, Cole, and Sniffin (1976) on the value of papaverine in T.D. The investigators observed a statistically significant reduction in the overall rating scale scores of nine patients treated with papaverine. Yet, a clinically significant improvement (50 percent or greater improvement) was seen in only two cases-the others showing a less than 33 percent drop in their severity of dyskinesia.
Presumed Specificity of Treatment
Effects. Even when a particular treatment is shown to be effective for relief of T.D., the underlying mechanism of action remains uncertain. Most drugs have multiple actions, and the possibility remains that a drug may not owe its efficacy to the specific action in which the investigator is interested. Thus, a number of investigators have attributed the transitory ameliorating effect of physostigmine to its cholinergic action. Yet, Tamminga et al. (1977) , who also noted a significant response to physostigmine, found a comparable improvement with methohexital, a sedative. They therefore entertained the possibility that physostigmine may owe its antidyskinetic effect to its sedative property rather than to its cholinergic action. It is well known that T.D. disappears during sleep, and is aggravated by anxiety. It is therefore advisable in conducting double-blind trials on drugs that also have sedative properties to use an active placebo with similar sedative action.
Side Effects of the Experimental Treatment. Deanol has been reported to produce peripheral cholinergic side effects in some patients (Rosenbaum et al. 1977) . Emergence of such symptoms during a double-blind trial is likely to make the study nonblind unless the placebo also produced similar side effects.
Analysis of Dropouts.
Several studies on relatively large numbers of patients report a significant proportion of dropouts from the experiment (Fann, Davis, and Wilson 1973; Gerlach, Thorsen, and Munkvad 1975; Reda, Escobar, and Scanlan 1974; Simpson et al. 1976 ). The reasons for dropping out are protean-e.g., side effects, lack of responsiveness, worsening of symptoms, and practical problems such as a family crisis. Unless the reasons for dropping out, when known, are specified, it may sometimes be difficult to interpret the overall effects of the experimental treatment.
Reporting Studies. It is probably a universal phenomenon that positive results of a treatment are reported more often than negative ones. This may serve to skew a literature review in favor of the positive studies. Probably the greatest number of T.D. patients reported in these studies have been treated by withdrawal of neuroleptics. Most of the investigators conclude that the proportion of T.D. that disappears when neuroleptics are withdrawn is highest in younger and nonbraindamaged subjects (Degkwitz 1969; Dynes 1970; Edwards 1970; Hunter, Earl, and Thornicroft 1964; Paulson 1968; Pryce and Edwards 1966; Turunen an Achte 1 1967; Uhrbrand and Faurbye 1960; Yagi et al. 1976) . Two studies found a high proportion of cases of persistent T.D. in patients given interrupted treatment (Degkwitz 1969; Jeste et al., in press ).
Discussion
Taken as a group, neuroleptics have been the most effective drugs for suppressing T.D. This creates an ethical dilemma in that the drugs used for treating T.D. are those that probably caused it in the first place. No. of patients very small
44.7
More than one drug treatment was tried at different times on the same patients in a few studies.
*X> Patients improved = (Patients improved X100)/(Patients improved + patients not improved).
There is a concern that continued administration of neuroleptics may make T.D. irreversible ), more severe, or both. In a long-term trial of two neuroleptics, however, Kazamatsuri, Chien, and Cole (1973) found no evidence of ill effects of the neuroleptic treatment on T.D. In another long-term study comparing the effects of neuroleptic administration versus neuroleptic withdrawal, Turek et al. (1972) noted significant improvement in T.D. during the periods of neuroleptic administration, and worsening with neuroleptic withdrawal. As already mentioned, the use of neuroleptics for treating T.D. may be compared to the use of opiates in the treatment of opiate dependence, although the two situations have some obvious differences. Another possibility, which has not been explored carefully, is that of development of tolerance to DA supersensitivity with continued neuroleptic treatment. Tolerance is known to develop for most other extrapyramidal, autonomic, and sedative side effects of neuroleptics (Davis and Cole 1975) . It is conceivable that similar tolerance may develop to tardive dyskinesia in at least some patients.
Although more studies have been done on deanol than on any other single drug for treating T.D., the value of deanol still remains questionable. Its mode of action as an ACh precursor has also not yet been conclusively demonstrated. Significant improvement in T.D. was reported in the majority of studies using physostigmine. However, in these trials the drug was administered intravenously on a single occasion, and its effects were studied. There is uncertainty about the duration of the effects of physostigmine on T.D. With nearly the same dose of the drug, Davis et al. (1976) found that the effects lasted for 2 hours, while Fann et al. (1974) noted maximum improvement 24 hours after the injection. Furthermore, Tamminga et al. (1977) have attributed the salutary effects of physostigmine to its sedative action. The hope of a successful cholinergic treatment for T.D.
has not yet materialized.
GABA'ergic drugs such as benzodiazepines have been reported to reduce symptoms of T.D. in some studies. Most of these investigations, however, were carried out in a nonblind design. There is a possibility that GABA'ergic drugs may exert their effect on T.D. as sedatives and not necessarily through their central GABA'ergic action. Well-designed studies on larger patient populations are needed before the value of GABA agonist agents in the treatment of T.D. can be properly assessed. The same holds true for nonneuroleptic DA antagonists.
There is a general consensus that antiparkinsonian agents-both anticholinergic (e.g., trihexphenidyl) and dopaminergic (e.g., amantadine or L-dopa) in the usual doses for the treatment of parkinsonism-do not help and may even aggravate the symptoms of T.D.
Possible Subtypes of T.D. Casey (1976) has suggested that there may be at least two subtypes of T.D., one of which responds to cholinergic drugs and the other to anti-DA agents. Some studies using various drugs on the same patients (Casey and Denney 1977; Nesse and Carroll 1976) are quoted as favoring this hypothesis. Although this is an interesting suggestion, more studies are warranted to validate it.
We (Jeste et al., in press ) have proposed that T.D. may be classified into persistent and reversible types. Response to withdrawal of neuroleptics for at least 3 months may be used as a criterion for judging reversibility of T.D. In all likelihood, patients with reversible T.D. respond to many nonspecific treatments, while those with persistent T.D. fail to benefit from most of the available treatments. It is interesting to note that approximately 35 to 45 percent of patients respond to many different types of drugs with dissimilar mechanisms of action (table 10) . Thus, in at least some cases, positive results may not have been due to specific actions of the drugs given, but to such nonspecific factors as placebo response, spontaneous remission, raters' bias, and concomitant treatments like milieu therapy, psychotherapy, or environmental modifications. These cases probably belong to the subgroup of reversible dyskinesia. It is also possible that dyskinesia induced by the withdrawal of neuroleptics may be more easily reversible than T.D. that develops during the course of neuroleptic treatment, although this remains to be studied.
Recommendations for Treatment of Individual Patients with T.D.
After a diagnosis of T.D. has been made in a patient on neuroleptics, an attempt should be made to discontinue neuroleptics. Other drugs that possibly aggravate T.D., such as antiparkinsonian agents, should also be stopped. The withdrawal of drugs should be gradual rather than abrupt. Ideally, the patient should then receive only nondrug treatments such as psychotherapy and milieu therapy. However, a majority of the patients will, at one time or another, require medications to control their psychiatric symptoms. In such cases, sedatives should be tried first. Should it prove necessary to prescribe neuroleptics, the psychiatrist would be well advised, for legal and ethical reasons, to obtain an informed consent. Preferably, a type of neuroleptic different from that administered to the patient in the past should be chosen. Giving the lowest effective amount of the drug, in divided daily doses (Jeste, Olgiati, and Ghali 1977) , is to be recommended. The patient's neurological status should be followed carefully. These recommendations are based on prevalent scientific opinion.
As can be seen in table 10, the most effective suppressant treatment for T.D. is neuroleptic administration. Although there is no convincing evidence that giving neuroleptics to patients with T.D. results in irreversible brain damage, this possibility has not been ruled out. Hence, following the traditional medical aphorism primum non nocere, routine use of neuroleptics for the treatment of T.D. cannot be recommended as the first line of attack. At the same time, there is an urgent need for detailed behavioral, biochemical, and neuropathological studies on the effects of neuroleptic administration in T.D. and its equivalents, including animal models.
Suggestions for Well-Designed Treatment Studies. The following suggestions strike us as most important to be considered in designing future studies.
1. Diagnosis of T.D. should be based on strict criteria (Jeste et al., in press ). It should be confirmed by at least two investigators independently, and be made by repeated, unobtrusive observations. 2. If possible, neuroleptics and other psychotropic medications should be withdrawn for at least 3 months before the study is undertaken. Most cases of reversible T.D. can thus be excluded. If this procedure is not feasible, neuroleptics and other drugs should be maintained at a stable dose level for at least 3 months before the study and 9. Reasons for dropouts should be analyzed. 10. Among the large number of potentially useful lines of research, the following now seem to be most pragmatic:
• Effects of continued neuroleptic administration in T.D. patients who require neuroleptics for the control of their psychotic symptoms-Such patients should be carefully monitored for various behavioral, biochemical and neuropathological changes. One aspect that has not been investigated is a possible relationship between T.D. and very low blood concentrations of neuroleptics found in some chronic schizophrenic patients.
• Specificity of drug actions-If patients responding to a certain drug also respond similarly to other drugs of the same family (e.g., cholinergic), but not to a different type of drug (e.g., dopamine blocking), the specificity of drug actions would be supported. 
